A placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability and pharmacokinetics of MAT2501 at up to three different doses in healthy volunteers

Trial Profile

A placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability and pharmacokinetics of MAT2501 at up to three different doses in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Amikacin (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 08 Aug 2017 According to a Matinas BioPharma media release, the company expects to commence ultiple-ascending dose PK/tolerability study of MAT2501 in healthy volunteers in Q4 2017.
    • 03 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top